Cipher Pharmaceuticals Inc.
TSX:CPH.TODrug Manufacturers - Specialty & Generic
+$0.15 today
- Market cap
- $331.67M
- Beta
- 0.48
- P/E (TTM)
- 9.3
- EPS (TTM)
- $1.22
Volume 0.04M
Average 0.03M
CPH.TO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Cipher Pharmaceuticals Inc.TSX: CPH.TO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $1.81M fell 0.8% year over year, behind the +30.0% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.1% from the prior quarter. Over 3 fiscal years it compounded at +94.1% a year.
Context
- Depreciation & amortization amounted to 14.1% of revenue in FY2025, up 2.0 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -0.8% toward the trailing-twelve-month pace of +30.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 7.23M USD
- Year-over-year change
- +80.0%
- 4-year CAGR
- +79.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.23M | +80.0% |
| FY2024 | 2024-12-31 | 4.02M | +227.4% |
| FY2023 | 2023-12-31 | 1.23M | +24.1% |
| FY2022 | 2022-12-31 | 989K | +41.1% |
| FY2021 | 2021-12-31 | 701K | — |
Depreciation & Amortization vs competitors
How CPH.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +30.0% is the 2nd highest of 8, against a peer median of -1.0%.
- Depreciation & amortization amounts to 14.2% of revenue for CPH.TO, versus a peer median of 7.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$61.18M CAD | +17.4% | -3.3% | 12.0% | |
| LTM Mar 2026 | CA$40.12M CAD | -6.9% | -23.0% | 12.9% | |
| LTM Mar 2026 | CA$19.76M CAD | +37.8% | — | 7.2% | |
| LTM Mar 2026 | $16.25M USD | -28.6% | -9.8% | 6.2% | |
| LTM Mar 2026 | CA$14.19M CAD | -37.1% | -31.2% | 4.5% | |
| LTM Mar 2026 | $7.22M USD | +30.0% | +94.1% | 14.2% | |
| LTM Mar 2026 | CA$253K CAD | +1.6% | -2.8% | 9.2% | |
| LTM Mar 2026 | $101.93K USD | -1.0% | — | 0.2% | |
| Peer median (excluding CPH.TO) | — | -1.0% | -9.8% | 7.2% | |
Competitors are the stored peer set for CPH.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.76M | 26.64M | 20.38M | 11.55M | 27.33M |
| Depreciation & Amortization | 701K | 989K | 1.23M | 4.02M | 7.23M |
| Deferred Income Tax | (114K) | (14.31M) | (2.74M) | (8.64M) | (10.36M) |
| Stock-Based Compensation | 139K | 403K | 1.19M | 1.07M | 1.74M |
| Change in Working Capital | 4.68M | (3.03M) | (3.28M) | 8.95M | 5.32M |
| Accounts Receivables | 2.56M | (144K) | 1.71M | (8.77M) | 2.7M |
| Inventory | (758K) | (502K) | (830K) | 3.6M | (2.44M) |
| Accounts Payables | (1.23M) | (1.45M) | 532K | 1.28M | 527.07K |
| Other Working Capital | 4.11M | (940K) | (4.69M) | 12.85M | 4.53M |
| Other Non-Cash Items | 652K | (109K) | (788K) | 2.6M | (1.01M) |
| Operating Cash Flow | 13.81M | 10.58M | 16M | 19.55M | 30.25M |
| Capital Expenditures | 0 | (81K) | (144K) | (44K) | (28.49K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 132.28K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (123K) | (80M) | 0 |
| Investing Cash Flow | 0 | (81K) | (144K) | (80.04M) | (72.24K) |
| Debt Repayment | (828K) | (56K) | (111K) | 39.79M | (35.61M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 218.76K |
| Common Stock Repurchased | (1.72M) | (1.99M) | (5.56M) | (176K) | (5.48M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 75K | 132K | 426K | (317K) | (311.36K) |
| Financing Cash Flow | (2.47M) | (1.91M) | (5.24M) | 39.3M | (41.18M) |
| Effect of Forex Changes | 62K | (292K) | 378K | (786K) | (194.92K) |
| Net Change in Cash | 11.41M | 8.29M | 10.99M | (21.99M) | (11.2M) |
| Free Cash Flow | 13.81M | 10.49M | 15.98M | 19.5M | 30.22M |
Cipher Pharmaceuticals Inc.
TSX:CPH.TO
Intrinsic Alpha fair value
Locked
Current Price
$13.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.